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Towards modern genetics, diagnostics and therapeutics of heart failure in a new eraHeart failure is a complex combination of symptoms based on mal-
function of either the left or right ventricle due to diminished contraction
or relaxation [1]. The number of causes is numerous, but predominant are
ischemic heart disease and hypertension [2]. The struggle to improve the
very poor prognosis in patients with symptoms is ongoing and steps to-
wards the beneﬁt of patients are beingmade. Not only is survival improv-
ing gradually, more important is improvement of the quality of life. What
is the value of a prolonged life without improvement of quality of life in
highly symptomatic patients? Although big pharma appears to be
stepping away from heart disease in general and heart failure more spe-
ciﬁcally, there are always new insights and potential targets that are
worthwhile to pursue [3]. In this special issue of BBA various groups
have contributed their insights in the current state-of-the-art and where
the new diagnostic and therapeutic targets can be found. The review pa-
pers go from early development and cardiogenesis through molecular
mechanisms of hypertrophy and failure. Here several important break-
throughs have been listed with even the ﬁrst modest steps to interven-
tions where especially the ﬁeld of the antagomirs seems to be an area
where the time gap between target recognition and therapeutic interven-
tion in man could be reduced considerably. Finally, there are contribu-
tions to discuss the value of molecular tools to improve our diagnostic
capabilities to recognize the disease and predict outcome.
Sergeeva and Christoffels focus on themolecular regulation of expres-
sion of atrial (ANF) and brain natriuretic peptide (BNP) during the early
steps of heart formation and in cardiac disease [4]. The mammalian
heart is known to express both natriuretic peptide (NP) hormones. The
physiological role of NPs is to act to increase natriuresis and decrease vas-
cular resistance, thereby decreasing blood volume, systemic blood pres-
sure and afterload. In addition, plasma levels of BNP are used as speciﬁc
markers for the differentiating working myocardium in the developing
heart and their gene structures serve as a platform to investigate gene
regulatory mechanisms in heart development and disease. NPs are also
widely used in biomedical research to assess the hypertrophic response
in cell culture or the development of HF in animal models. Finally, NPs
are clinicallywidely used as diagnostic and prognosticmarkers for hyper-
trophy andheart failure. However, despite decades of research, themech-
anisms regulating the NP genes during development and disease are not
well understood and in their review Sergeeva and Christoffels update
the ﬁeld on the regulation of expression of the genes for ANF and BNP
and their role as biomarkers, and give future directions to identify the
in vivo regulatory mechanisms.
Dirkx and DeWindt zoom in on the gene regulatory mechanisms un-
derlying the so-called fetal gene program [5]. Cardiomyocyteswill react to
biomechanical stress by activating pathways that induce either apoptosis
[6] or pathological hypertrophy [7], where hypertrophy forms an inde-
pendent risk factor for the development of heart failure [8]. Accompanied
with hypertrophy are gene expression patterns and molecular changes0925-4439/$ – see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.bbadis.2013.10.010that bear resemblance to those observed during fetal cardiac develop-
ment as previously discussed by Sergeeva and Christoffels [4]. The re-
activation of fetal genes in the adult failing heart is a complex biological
process that involves transcriptional, posttranscriptional and epigenetic
regulators of the cardiac genome. In this overview, the mechanistic ac-
tions of transcription factors, microRNAs [9] and chromatin remodeling
processes in regulating fetal gene expression in heart failure is discussed
in more depth.
Ather and colleagues focus on alterations in Ca2+ release and reuptake
during excitation–contraction coupling [10]. These processes start within
the dyadic region, where the adjacent transverse (T)-tubules and SR
membranes allow RyR2 clusters to release SR Ca2+ following Ca2+ inﬂux
through adjacent LTCCs. SR Ca2+ released during systole binds to
troponin-C and initiates actin–myosin cross-bridging, leading to muscle
contraction. During diastole, the cytosolic Ca2+ concentration is restored
by the resequestration of Ca2+ into the SR by SR/ER Ca2+-ATPase
(SERCA2a) and by the extrusion of Ca2+ via the Na+/Ca2+-exchanger
(NCX1). This process is highly coordinated and determines the force of
contraction, providing a link between the electrical andmechanical activ-
ities of cardiac muscle. In heart failure, the heart undergoes maladaptive
changes that result in depressed intracellular Ca2+ cycling and decreased
SR Ca2+ concentrations. As a result, the amplitude of CICR is reduced
resulting in less force production during EC coupling. In this review, the
speciﬁc proteins that alter the regulation of Ca2+ duringHF are discussed,
with a particular focus on defects in RyR2-mediated SR Ca2+ release.
Heart failure is also associated with ventricular arrhythmias, at times
leading to sudden cardiac death. The electrophysiological remodeling is
reviewed by Coronel and changes in intracellular calcium handling are
discussed. Intercellular uncoupling and ﬁbrosis are identiﬁed asmajor ar-
rhythmogenic factors. Both factors contribute to the origin of the arrhyth-
mic substrate. Modulating factors like diet and ventricular wall stress are
discussed. A special section is focusing on. Finally, emphasis is placed on
right ventricular failure.
Gaggin and Januzzi comprehensively introduce the rapidly changing
ﬁeld of clinical heart failure diagnostics and prognostics [11]. Heart fail-
ure biomarkers have impacted the way HF patients are evaluated and
managed with B-type natriuretic peptide (BNP) and N-terminal proBNP
(NT-proBNP) serving as the gold standard biomarkers in determining
the diagnosis and prognosis of the disease, and natriuretic peptide-
guided heart failure management looking promising. New and exciting
biomarkers are also emerging, each reﬂecting different pathophysiolog-
ical processes in the development and progression of heart failure,
more closely reﬂectingmyocardial insult, inﬂammation and remodeling.
Novel biomarkers such as mid-regional pro atrial natriuretic peptide
(MR-proANP), mid-regional pro adrenomedullin (MRproADM), highly
sensitive troponins, soluble ST2 (sST2), growth differentiation factor
(GDF)-15 and Galectin-3, show potential in determining prognosis
2402 Preface to heart failurebeyond the established natriuretic peptides, likely serving a role as addi-
tional biomarkers in multiplexed biomarker platforms.
Finally, Lopes and Elliot present the evidence that the risk of heart fail-
ure in the general population depends on genetic predisposition [12]. In a
small, but probably underestimated proportion of the population, heart
failure is caused by Mendelian inherited forms of myocardial disease.
The genetic background of these genetic conditions is a matter of inten-
sive research and the results of these efforts are also shedding light onto
the genetics andmechanisms of common forms of heart failure. In this re-
view, the insights provided by candidate gene and genome-wide associa-
tion approaches in common heart failure are described and the authors
go on to update themain genetic causes of inherited heartmuscle disease
and give the current challenges and future research needs for both forms
of heart failure.
Composing the special section was very rewarding. We hope that
reading the papers is even more stimulating, and will help to revive in-
terest in the fascinating ﬁeld of cardiac pathophysiology.
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